MCP & A2A (Agent2Agent) protocol, clearly explained (with visuals): ...

Does Hyperliquid fit in the ‘fat app’ or ‘fat protocol’ camp??? ...

[Applause] [Music] Your mood changes every day and for many reasons. But do you know the causes. Today we're going to discuss something quite fascinating.The small microbes in our body and how they affect our mood. That's correct, Noah. When we think about our bodies, we think mostly about organs, muscles, and bones.But we're also a host of trillions of microbes, mostly bacteria, that are living inside of our body. These microbes aren't just along for the ride. They're actively involved in many processes of ...

[Music] Thank you everyone for coming here. I hope you're uh excited to figure out with me what enterprise ready MCP means. Uh I'm not sure a month ago people even fully understood what MCP meant.Um so we're all on this journey together. Um, but hopefully it should be fun. So, I was chatting to a good friend and colleague who is is giving a talk tomorrow on building MCP servers and what it looks like to build that out.And his question was, how do the tools of today map to the AI systems of tomorrow. We alre ...

Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative Breast Cancer FLORHAM PARK, N.J. and WEST VALLEY CITY, Utah, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Nusano, a physics company transforming the pro ...

Core Insights - ZyVersa Therapeutics, Inc. has initiated patient recruitment for its VAR 200 Phase 2a clinical study targeting diabetic kidney disease (DKD) [1][2] - VAR 200 is designed to address renal lipotoxicity by removing excess lipids from the kidneys, which is a significant factor in the progression of kidney diseases [3][7] - The study aims to evaluate the efficacy and safety of VAR 200 in patients with type 2 diabetes and DKD, with preliminary data expected in the second half of 2025 [7] Company Overview - ZyVersa is a clinical stage specialty biopharmaceutical company focused on developing first-in-class drugs for renal and inflammatory diseases with significant unmet medical needs [8] - The company is advancing a therapeutic pipeline that includes VAR 200 and another program targeting inflammation [8] Clinical Study Details - The VAR 200 Phase 2a trial will be an open-label study conducted at one to two US sites, enrolling an adequate number of subjects to complete eight [2][7] - The primary efficacy endpoint is the percent change from baseline to week 12 in urinary albumin to creatinine ratio, with treatment lasting 12 weeks followed by a four-week follow-up [2][7] Drug Mechanism and Indications - VAR 200, a Cholesterol Efflux Mediator™, is an injectable drug that aims to reduce renal lipid accumulation, which damages the kidney's filtration system [3][5] - Preclinical studies have shown that VAR 200 can reduce cholesterol and lipid levels, protect against renal injury and fibrosis, and improve proteinuria in various kidney disease models [4][7] Future Prospects - The lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS), with plans to expand indications based on the results of the ongoing trials [5][7] - The initiation of patient recruitment is considered a key milestone in the development of VAR 200, with the potential to be a first-in-class treatment for kidney disease [7]

For this blog post I would like to thank... myself for posting this tweet.New protocol hunting is highly profitable strategy. But it requires knowledge, time, and some capital.https://t.co/ifpUNblPalIgnas | DeFi (@DefiIgnas):I'm getting less motivated to chase hot new protocols.Lazy? Bored? Not quite, I think.Or maybe it's not worth the risk of exploitation for a relatively small airdrop?Maybe there are too many new projects with just incremental improvements... without real 0 to 1 innovation? ...

How to Find Tokenless Protocols Worth Your TimeIn this blog I'll share:- 7 tools I use to find hot projects- 7 dApps to check out- 5 crypto bloggers to followRead it here:https://t.co/4ELEJIhPcN ...

Core Insights - Coherent Corp. will showcase its innovative photonics products and technologies at Laser World of Photonics 2025 in Munich, Germany, from June 24-27 [1][2] - The event serves as a global platform for demonstrating advancements in photonics, highlighting Coherent's role in shaping the industry's future through transformative technologies and partnerships [2] Recent Product Announcements - The introduction of an industry-first 600W excimer laser that doubles throughput and triples runtime for high-volume HTS tape production, supporting applications in fusion energy and MRI [3] - Launch of an 18W 880 nm single-emitter laser diode designed for efficient pumping of DPSS lasers, enhancing performance in industrial and scientific applications [4] - A new two-micron thulium fiber laser aimed at improving precision and efficiency in urology treatments, offering compact and energy-efficient solutions [5] - High-performance disposable surgical fibers designed for laser lithotripsy and medical procedures, providing superior durability and energy transmission [6] - A compact 500W air-cooled diode laser system for polymer welding, simplifying OEM integration and enhancing productivity [7] - The FACTOR series diode pumps now feature higher output power and new wavelengths, supporting scalable production for medical and industrial applications [8] - The expanded PowerMax™ line includes a new high-power sensor capable of measuring laser power up to 15 kW, enhancing safety and accuracy in industrial environments [8] Integrated Photonics Forum - The opening keynote titled "Unlocking Revolutionary Frontiers in Technology" will be presented by Dr. Sanjai Parthasarathi on June 24 [9] - Various talks and panel discussions will cover trends, challenges, and advancements in the industrial laser industry, featuring multiple expert speakers throughout the event [15]

Welcome to the Launching the Field-Oriented Control, FOC, motor control application using the KD240 Drive Starter Kit demonstration. The demonstration begins with an overview of the AMD Vitis motor control libraries used for field-oriented control, followed by setting up the AMD Kria KD240 Drive Starter Kit with the AMD Kria KD240 Motor Accessory Pack. It then covers booting the starter kit, loading the firmware, and running the motor control application.This demo requires the Kria KD240 Drive Starter Kit, ...